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Summary.-Simultaneous measurement of neutrophil migration, phagocytic
activity, candidacidal and bactericidal activity were made during quadruple chemo-
therapy of advanced Hodgkin's disease (HD). Measurements were also made in
normal individuals, hospital patients not on chemotherapy, untreated patients with
advanced HD and patients off chemotherapy for over a year.
Neutrophil migratory activity was usually normal in untreated HD patients and
those on chemotherapy, but >200O ofall tests showed depressed values, some ofwhich
were corrected by plasma. Similar results were found with neutrophil phagocytosis.
Abnormalities in these functions were found in both early and late cycles, but there
was a tendency for migration to deteriorate during later chemotherapy cycles.
Neutrophil candidacidal and bactericidal activity were frequently depressed in
patients on treatment and there was deterioration in candidacidal activity during
the chemotherapy cycle. These abnormalities of killing activity were frequently
corrected in control plasma.
Neutrophil function is normal in most patients with advanced HD and in patients
in remission. In a minority of patients on treatment there are marked functional
defects, especially in killing activity. These defects are partly cell-associated and
partly plasma-related. Susceptibility to infection during chemotherapy of HD may
be partly due to defective neutrophil function.
PATIENTS WITH HODGKIN'S DISEASE
(HD) are susceptible to infection both as
a result of the disease and its treatment.
Depression of cell-mediated immunity is
a well recognised accompaniment of ad-
vanced disease (Aisenberg, 1971) which
contributes to the susceptibility to virus
infections, especially herpes zoster (Arvin
et al., 1978) and opportunistic organisms.
Other mechanisms of host defence have
been less well studied. Neutrophil function
has been the subject ofsome investigation,
but reported studies have usually con-
cerned themselves with single aspects of
neutrophil function, and have not always
distinguished between the effects of
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disease and of treatment. Results have
therefore been conflicting; neutrophil
microbial-killing activity for example be-
ing reported as depressed (Lehrer & Cline,
1971) or normal (Steigbigel et al., 1976;
Hancock et al., 1976).
We have studied several white-cell
functions simultaneously in patients with
advanced HD over many cycles of com-
bination chemotherapy. The aim has been
to relate abnormalities in host defence
function to clinical infection, and to
attempt to develop a host defence "screen"
capable ofpredicting the onset ofinfection
in immune-compromised patients by
simultaneous measurement of WBC num-84. GAND)OSSTNI ET AL.
bers and function. The present paper
decribes neutrophil migratory, phagocytic
and killing activity in HD and the effect
of chemotherapy on these functions. The
results of tests on monocyte functioin and
leucocyte numbers performed at the same
time will be reported separately.
METHODS
Preparation of leucocytes.-50 ml of blood
w%Nas mixed with 10 ,ug/ml preservative-free
heparin. A 3ml aliquot wsras mixed with
Plasmasteril (Fresenius) in equal volume and
left to stand for 20 min at room temperature.
The leucocyte-rich supernatant was washed
in a working medium consisting of antibiotic-
free RPM1 containing 01°o bovine serum
albumin (BSA) and in 20mM HEPES. The
cells were suspended at 2 x 106/ml and this
suspension was used in all tests of neutrophil
function. The average cell composition was
79-90o neutrophils, 12*6° lymphocytes, 7-5o
monocytes for both controls and patients.
All function tests were carried out in both
autologous and control plasma. Control
plasma was obtained from the normal control
subject who was tested with each batch of
samples. The small percentage of contaminat-
ing monocytes does not interfere w%ith the
interpretation of the data. In the phagocy-
tosis and killing assay, monocytes can be
identified easily and are not scored. In the
migration assay the pore size used for neutro-
phils does not admit monocytes, which in
any event migrate more slowly and can be
identified by nonspecific-esterase staining.
Monocytes do not kill Pseudomonas signifi-
cantly in the conditions used.
Neutrophil Pseudomonas killing. The
method was a modification of that of Grogan
& Miller (1973). Pseudomonas aeruginosa was
used at a final concentration of 106/ml.
041 ml of cells (2 x 106/ml), 0-2 ml of organ-
isms and 0-05 ml of autologous or control
plasma were mixed for 60 min at 37°C,
followed by the addition of 0-1 ml of 2%
sodium deoxycholate. 01 ml of the super-
natant was then placed in 2-5 ml nutrient
broth, plated on to McConkey agar plates,
incubated overnight and the colonies then
counted. Tests wAere carried out in duplicate,
with control or autologous plasma, and 00 kill
wAas determined by the reduction in colony
count as compared with the same procedure
in the absence of neutrophils.
Neutrophil Candidaphagocytosis and killing.
-We used a modification of the technique of
Lehrer (1970). C. guillermondii was the test
organism. In preliminary experiments it wTas
found that, although a ratio of 4 organisms
to 1 neutrophil gave a higher phagocytic
index, at this ratio the assessment of killing
was difficult because of the distension of the
cytoplasm with yeasts. Because wNe wished
to combine measurement of phagocytosis and
killing in the same test we chose a 2:1 ratio.
The neutrophil suspension (0-2 ml) Candida
and plasma (14% control or autologous)
were incubated at 37°C. Phagocytosis wras
assessed at 15 min and killing at 60 min.
Cytocentrifuge preparations were made, and
stained with May-Griinwald Giemsa. 200
neutrophils were observed and the average
number of Candida per neutrophil expressed
as the phagocytic index. The number of dead
Candida per cell was called the killing index.
The phagocytic and killing indices are
frequently >2 because the whole cell sus-
pension was not of pure neutrophils, and
because some degree of Candida multiplica-
tion probably occurred during the culture.
Although phagoeytosis is better assessed by
an assay which measures rate of ingestion,
this was not compatible with our aim of
measuring several functions simultaneously
in the same patient. In preliminary experi-
ments we found that phagocytosis at the
neutrophil/Candida ratio chosen was com-
plete in normals in 20-30 min. The test as
performed is therefore able to demonstrate
defective phagoeytosis. Similarly, Candida
killing was usually complete in normals at
60-75 min.
Neutrophil migration.-This technique has
been described in detail by Addison &
Babbage (1976). It is a membrane-migration
technique allowing the simultaneous com-
parison of several samples. The tests were
carried out in duplicate in both control and
autologous plasma. The leading front was
determined in microns, at 250 x mag-
nification.
PATIENTS
Thirty-three patients were studied over
a total of 72 treatment cycles. Since many
patients had low cell counts, it was not pos-
sible to do all tests on every occasion. Nine-
teen patients off treatment for more than a
year were also studied. All patients had
histologically proven HD and were of
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advanced stage (IIIB or IV). Sixteen of 33
patients had had previous radiotherapy.
Chemotherapy was quadruple therapy with
MOPP or MVPP. Mustine and either vin-
cristine or vinblastine were given on Days
1 and 8 i.v., and oral procarbazine and predni-
solone on Days 1-14. Eight patients received
chlorambucil (10 mg) daily for 2 weeks
instead of mustine because of nausea. Many
patients were studied serially through several
cycles. Eighteen patients had been on chemo-
therapy before being studied, but 15 were
studied during the first and subsequent
cycles. Patients were bled on Day 1 before
starting treatment, Day 8 before the 2nd
injections and Day 14, the last day of the
cycle. Controls were either normal laboratory
personnel and students, or hospital patients
without cancer or infection and not on cyto-
toxic agents.
Expression of results.-A sample from the
non-hospitalized controls was always included
in each batch of samples from patients.
Previously (Addison et al., 1978) we have
expressed results as a proportion of this
control, but the variability of the data is not
diminished by this method. In detailed com-
parisons between the two methods we have
found the same patterns of abnormalities
in the patients. The inclusion of normal
controls in every assay allowed us to be sure
that the experiments were technically satis-
factory on that day. We have therefore
presented the results as absolute values and
included the data from the control popula-
tions. When comparisons are presented
between the values obtained in autologous
and control plasma, "improvement" refers
to the return of a depressed value to within
2 s.d. ofthe normal mean.
Statistical analysis.-For the analyses of
variance, all variables were transformed by
taking square roots before analysis, to stabil-
ize variances. Differences between days of
the cycle were examined using a 3-factor
(patients, cycles within patients and days of
the cycle) analysis of variance; differences
between patients and between cycles were
regarded as "random" effects, differences
between days ofthe cycle as "fixed". Pairwise
comparisons between the means of different
days were made using the least significant
difference (Snedecor & Cochran, 1967). Dif-
ferences between the first days of the earliest
and latest cycles in the same patients were
analysed using the paired t test. In all
analyses, P=0 05 was set as the level for
statistical significance. Comparison of values
between patients and controls was made using
an unpaired, 2-tailed t test. The values for
the results on each day are presented as
actual values for clarity and the statistical
analysis made on this untransformed data.
When the data is transformed into square
roots and analysed, the tests for statistical
significance give identical results.
RESULTS
Migration
The results of the tests of neutrophil
migration are shown in Fig. 1. The mean
distance of migration in normal controls
was 91 1im (range 60-120); the hospital
control population was similar (mean 102
,um, range 71-125). Although mean values
for patients on chemotherapy were not
significantly lower than for the control
populations, the range of values was very
much wider, some patients showing very
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FIG. 1. Neutroplil migration: A = NTormal
controls (91-8 +12-3, n=43), B=Hospital
controls (102-4 +11-9, n=45), C=Day 1
of chemotherapy (84-2+23-0, n=54), D=
Days 8/14 of chemotherapy (80-0+19-6,
n = 54), E =Untreated patients (83-0 + 22-8
n = 12), F = Patients off treatment for i
year (82-0 + 16-0, n= 19). Columns C and D
include only those patients where measure-
ments were made on both Day 1 and 8/14.
-2SwD -A-
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defective migration-more than 2 s.d.
below the normal population. These ab-
normal results were seen on each of the
3 days ofthe cycle, and were also found on
Day 1 in 3/12 previously untreated
patients. Five patients who had been off
treatment for 12 months had values just
outside 2 s.d. below the normal mean. The
analysis of variance for all cycles where
values were obtained on each ofthe 3 days
("complete cycles") showed that there was
no significant difference between the
means of Days 8 and 14. The data for
these 2 days in each cycle were averaged
for each patient and the number of
patients in the analysis is increased by
including patients for whom data were
available only on Day 8 or on Day 14.
When all chemotherapy cycles were
analysed together there was no evidence
of a fall in migration within a cycle: the
Day 1 values were not significantly differ-
ent from those ofDays 8 and 14. However,
in those individuals who were studied
through more than one complete cycle,
when the fall in migration from Day 1 to
8/14 in early cycles was compared with
that in the later cycles there was a slight,
but significant (P < 0.05) tendency to a
more pronounced fall with the later cycle.
There was a significant variation in the
response of individual subjects during the
cycle (subject x days interaction) some
showing improvement, others no change,
others a deterioration. There was no
significant difference between the Day 1
means of patients who were studied in
both early and late cycles (Table I) indi-
cating no fall with repeated chemotherapy.
TABLE I. Differences
tion between earliest
Day 1
Mfigra-
tion
n 20
Mean diff. -0-06
s.e. 0-38
t test 017
(cell non-significant)
in neutrophil func-
and latest cycles at
Ps.*
kill
-0-06
0-92
0 07
Cd.t
Phago-
cytosis
5
0-18
0-82
0-22
* Pseudomowos aerugittosa.
t Candid(i guillermonidii.
Square root transformation of (lata. t test witlh
2 d.f. Av-erage number of cycles between earliest
an(d latest cycles = 2-55 (range 1-6).
TABLE II. Functional abnormalities of
neutrophils showing improvement in con-
trol plasma in all abnormal tests where it
was possible to carry out the measurement
in autologous and control plasma simul-
taneously. Improvement is defined as a
return to within 2 s.d. of the mean of the
normal controls (No. improved/total ab-
normal specimens)
AMigrattion
Cd. phagocytosis
Cd. kill
Ps. kill
Total improved1
Dlay 1
6/17
2/4
3/4
7/13:
23/32
Day 8
6/9
2/7
1/8
11/15
26/36
Day 14
1/6
1/4
4/11
5/10
20/31
Total
13/32
5/15
8/23
23/38
69/99
In 13/32 cases in which migration in
autologous plasma was reduced, it became
normal on testing in control plasma
(Table II). In those tests where function
was improved by control plasma, the
values returned to a normal mean and
range (Table III). The inhibitory effect of
plasma was as frequent on Day 1 (before
chemotherapy) as on Days 8 and 14, and
TABLE III.-Degree ofimprovement in neutrophilfunction in controlplasma
AN11gration (Lim)
Cd. phagocytic index
Cd. killing index
Ps. 0 kill
Abnoirmal
-alues in
auitologous
plasma
49-3 + 14 8
0 95+0 34
0-67+00-16
31-3 + 18-8
Control plasma
Not
Improved improx-ed
80-0+ 10-6 52 0+ 10.0
1-95+0-55 1-06+0-31
0.99+0-08 0-60+0-21
75-9 + 10.6 45-2 + 12-0
Values are mean + s.d. in each group. Abnormal values in auitologous plasma were those outside 2 s.d.
of the normal controls. Tests were (lesignatect as improved in control plasma if they returned to within 2 s.d.
Ofthe control mean.
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TABLE IV.-Effect of autologous plasma on
function tests on neutrophils inpreviously
untreated patients (No. abnormal/total
tested)
Abnormal tests* in
autologous plasma
Migration
Cd. phagocytosis
Cd. kill
3/12
2/8
3/7
* All functioned normally in control plasma (i.e.
returned to within 2 s.d. of control mean).
also occurred in 3/12 tests on previously
untreated patients (Table IV). In 3/5
patients who had been off treatment for
12 months and who had values more than
2 s.d. below normal, normal values were
obtained when tested in control plasma
(Table V).
Candidaphagocytosis
The 2 control populations gave similar
values for phagocytosis (Fig. 2). The
phagocytic index (PI) in patients on Day 1
of the cycle was slightly lower than in the
control groups (P < 0-02). The mean value
was further depressed (compared with
control) on Days 8 and 14 (P< 0.001). This
fall from Day 1 to 8/14 was statistically
significant (P < 0-05). The analysis of
variance, however, showed no significant
change between Day 1 ofthe earliest cycle
and Day 1 of the latest cycle (Table I).
The low values of PI in some patients
were in part due to plasma factors (Tables
II and III). Five of 15 low PJs were im-
proved by the addition of control plasma.
This effect of plasma was found on each of
the 3 test days.
Of the 8 untreated patients, 2 had a
depressed PI, which was corrected in
normal plasma in each case (Table IV).
Only 1 of the patients off treatment for a
year had abnormal PI and this was not
corrected by normal plasma (Table V).
TABLE V.-Effect of autologous plasma on
neutrophil function tests in patients off
treatment for 1 year (No. abnormal/total
tested)
Migration
Cd. phagocytosis
Cd. kill
Abnormal
5/19
1/14
2/14
Impro-ved in
control plasma*
3/5
0/1
1/2
4,
V
0
0
c 04 _
00 ** 00o
C. 0 1- * : *
c- -2SDI * a-i
A B C D .. F
FIm. 2. Neutrophil Candida phagoeytosis:
A=Normal control (2-51+0-56, n= 24),
B=Hospital controls (2-5+0 7, n=15).
C=Day 1 of chemotherapy (2-0+0-6, n=
14), D =Day 8/14 of chemotherapy (I1-54 +
0-58, n = 14), E =Untreated patients (2-0 +
0-6, n =8), F =Patients off treatment for I
year (2-35 + 0-43, n= 14). Columns C and D
include only those patients where measure-
ments were made on both Days I and 8/14.
* Returned to within 2 s.d. ofcontrol mean.
Candida killing
The hospital control population had a
slightly lower mean killing index than the
normal controls (Fig. 3). The values on
Day 1 of the chemotherapy cycle were the
same as in normal controls but the Day
8/14 values were depressed from 1-43 to
0-9 (P<0-001). The analysis of variance
confirmed a significant variation of killing
index in different days in the cycle
(P<0-01). Plasma factors were involved
in the abnormal killing in 8/23 observa-
tions (Tables II and III). There was no
correlation between the occurrence of
plasma factors and the day of the chemo-
therapy cycle.
Relationship between Candida killing defects
and phagocytosis
There was an association between
Candida killing and Candida phagocytosis
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FIG. 3.-Neutrophil Candida Killing: A=
Normal control (1-43+0-27, n=22), B=
Hospital controls (1-18+0-36, n=15), C=
Day 1 ofchemotherapy (1-50 + 0-52, n = 13),
D = Day 8/14 of chemotherapy (0-87 + 0-31,
n= 13), E =Untreated patients (I1-16 + 0 44,
n = 7), F =Patients off treatment for 1 year
(1-26+0-32, n=14). Columns C and D in-
clude only those patients where measure-
ments were ma(le on bothi Days 1 and 8/14.
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normal plasma had no effect. The effect of
plasma on improving killing was therefore
usually produced by improved PI.
Bactericidal activity
The results ofthe tests ofkilling activity
TABLE VI. Reversal of depression of
phagocytosis and killing by neutrophils in
control plasma
In control plasma
Nlormal kill
normal
phagocytosis Unimproved
In autologous plasma
Low kill, low
phagocytosis
Low kill, normal
phagocytosis
lOc
80
* 0
* 0
1 2
Candida kill index
a)
_x 60
U) E
0
0
20
3
FiG. 4. Relationship between neutrophil
Candida phagocytic an(d killinig activity.
r=0-63, 1'<0-00l.
(Fig. 4). In the tests showing defect in
killing, there was often a low PT (Table
VI). Twelve of 23 abnormal killings were
associated with low PI, and in all these
cases PI and killing were both improved in
normal plasma. Where neutrophil PI was
normal but killing depressed (11 cases),
12
0
0
11
FIG. 5.-Neutrophil Pseudomonas killing:
A =Normal control (77 0 + 8-5, n = 19), B =
Hospital controls (77-0+ 13-2, n=21), C=
Day 1 ofchemotherapy (52-9 + 27-8, n = 24),
D =Day 8/14 of chemotherapy (44/7 +
24-9, n = 24). Columns C and D include only
those patients where measurements were
made on both Days 1 and 8/14.
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of neutrophils in the control groups and
during treatment are shown in Fig. 5. The
means for normal and hospital controls
were both 77%. The mean Day 1 value in
the patients on chemotherapy was de-
pressed to 5299% (P < 0 01) and the Day 8
and 14 values to 45.750 (P<000l); the
difference between Day 1 and 8/14 is not
significant. The low values were commonly
due to plasma effects, being corrected in
normal plasma in 23/38 tests (Table II).
This correction occurred at all days of the
cycle. As with the other function tests, the
degree of improvement in control plasma
was sufficient for the values to return to a
normal mean and range (Table III). There
were no measurements made in untreated
patients and patients off treatment. Earlv
and late-cycle Day 1 values were the same
(Table I).
IDISCUSSION
Previous studies of neutrophil function
in cancer patients have usually measured
one function alone, and have usually failed
to distinguish between the effects of
chemotherapy and those of the disease.
This study is the first to use multiple
measurements of function in groups of
patients who are untreated, or on chemo-
therapy, or who have completed treat-
ment.
Neutrophil migration in patients with
untreated HlD is usually normal, but a
minority show depressed values. During
chemotherapy also, the patients' neutro-
phils usually migrate normally but in
some instances (- 200 %) the values are
depressed. Of 30 patients whose neutro-
phil migration was studied through one or
more complete cycles of chemotherapy, 17
had a depressed value on one or more
occasions. This depression is present on
Day 1, before chemotherapy, as well as on
Days 8 and 14. The Day I values of early
and late cycles are the same, but there is a
tendency for migratory activity to fall
during chemotherapy in the later cycles.
Many ofthe depressed values are corrected
in control plasma, and this inhibitory
effect ofplasma is equally frequent on each
59
ofthe 3 days ofthe cycle, and in a minority
of untreated and remission patients. This
indicates that circulating cytotoxic agents
are not wholly responsible for the defective
migration associated with plasma. The
nature of the inhibitory plasma factors is
obscure. Ward & Berenberg (1974) de-
scribed a factor in the serum of patients
with HD which reduced the effect of
serum chemotactic stimulus, but the
plasma components which cause chemo-
taxis may also cause increased neutrophil
mobility (chemokinesis) and thereby in-
crease undirected migration. Serum in-
hibitors might block this increased
mobility. Maderazo et al. (1978) have con-
firmed the presence of serum factors in
cancer patients which inhibit leucocyte
chemotaxis. Clearly, defective neutrophil
migration in vivo might play a part in
susceptibility to infection, but our data
shows that this defect only occurs in a
minority of untreated patients and that
chemotherapy does not appear to produce
a major additional defect, though with
repeated cycles of chemotherapy a greater
fall is seen during the chemotherapy cycle.
Defective neutrophil migration was also
found in 5/19 patients off treatment for
more than a year, and a plasma defect was
responsible in 3. The 5 patients are at
present in complete clinical remission, and
the significance of the persistent defect is
not clear.
The phagocytic activity of neutrophils
is also usually normal, but again a minority
of untreated patients have defective
phagocytosis, and we found a tendency,
which was significant statistically, for
chemotherapy to cause further impair-
ment. Our observations are similar to
those of Sbarra et al. (1964), who found
defective bacterial phagocytosis in neutro-
phils of lymphoma patients, and showed
that this was often corrected by normal
serum. We have also shown that plasma
effects are responsible, at least in part, for
defective phagocytosis of Candida in 5/15
patients on chemotherapy on the days
both before and during drug treatment. It
is not known whether the plasma effects
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are due to the presence of factors which
inhibit phagocytosis or to absence of
stimulating factors. On the other hand
Lehrer & Cline (1971) found neutrophil
phagocytosis to be normal in patients
with HD on chemotherapy, but they used
a lower Candida/cell ratio, which may have
presented a lesser phagocytic challenge.
Davies et al. (1976) have shown that cyto-
toxic agents can impair neutrophil phago-
cytosis in vitro and in patients on treat-
ment.
There is proportionately a greater im-
pairment of Candidacidal and bactericidal
activity of neutrophils than of the other
functions. In the case of Candida killing,
the defect is related to chemotherapy, the
neutrophils from most untreated patients
being normal, as are those from patients
off treatment. When the low Candida
killing index was associated with defective
phagocytosis, both abnormalities were
usually corrected by control plasma. In
contrast, when phagocytosis was normal,
depressed killing was not affected by con-
trol plasma. This result demonstrates the
importance of carrying out simultaneous
measurements of phagocytosis and killing
where possible. Defective Candida killing
in these patients can therefore be a result
either of defective phagocytosis related to
plasma factors or ofa cell-associated defect
in the presence of normal phagocytosis.
Pseudonomas killing is markedly im-
paired during chemotherapy, and this
effect is often attributable to plasma fac-
tors. This result confirms the finding of
Sbarra (1964) but contradicts that of
Steigbigel et al. (1976) and Hancock et al.
(1976), who found normal bactericidal
activity. This discrepancy may be partly
due to technical factors, since, in the
experiments of Steigbigel et al., the tests
were carried out using longer incubation
with bacteria, and delay in phagocytosis
and killing would not have been detected.
This study therefore shows that
patients with HD on chemotherapy
usually have normal neutrophil migratory
activity butphagocytic andkillingactivitY
is frequently depressed. Although these
defects are also found in a minority of
untreated patients, the Candida phago-
cytic and killing defect worsens as the
chemotherapy cycle proceeds. While circu-
lating cytotoxic drugs may be responsible
for some of the defects during the cycle,
the nature of the plasma factors respon-
sible for defective function on Day 1 of
chemotherapy and in untreated patients
is unknown. Defective neutrophil function
may increase susceptibility to infection.
particularly if more than one function is
defective simultaneously in the same
patient, as is the case with phagocytosis
and killing. We have also shown that other
aspects of host defence, such as monocyte
function, are affected in these same
patients and that severe lymphopenia
develops during the treatment cycle. The
relationship between defective neutrophil
and monocyte function and leucocyte
number and clinical infection will be re-
ported separately. Defective neutrophil
function may therefore be one component
of a variety of host defence abnormalities
which put HD patients with advanced
disease at risk of infection during treat-
ment.
AICB is suppoited by the Medical Researel
Council and Cancer Research Campaign. We thianik
Dr T. MecElwain for letting u;s study some of hiis
patient,s.
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